Bolt Biotherapeutics reported a quarterly loss of $4.31 per share, missing the Zacks Consensus Estimate of a $2.85 loss. The loss also widened versus $5.8 per share a year ago, indicating continued weak profitability despite year-over-year improvement in the loss magnitude. The miss is negative for sentiment and could weigh on the stock, though the article provides no revenue or guidance details.
Bolt Biotherapeutics reported a quarterly loss of $4.31 per share, missing the Zacks Consensus Estimate of a $2.85 loss. The loss also widened versus $5.8 per share a year ago, indicating continued weak profitability despite year-over-year improvement in the loss magnitude. The miss is negative for sentiment and could weigh on the stock, though the article provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.46
Ticker Sentiment
